Concepedia

Bimekizumab versus Adalimumab in Plaque Psoriasis

Richard B. Warren, Andrew Blauvelt, Jerry Bagel, Kim Papp, Paul S. Yamauchi, April W. Armstrong, Richard G. Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher L. Cioffi,

New England Journal of Medicine · 2021 · 217 citations · 11 references

DOI

Abstract

In this 56-week trial, bimekizumab was noninferior and superior to adalimumab through 16 weeks in reducing symptoms and signs of plaque psoriasis but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are required to determine the efficacy and safety of bimekizumab as compared with other agents in the treatment of plaque psoriasis. (Funded by UCB Pharma; BE SURE ClinicalTrials.gov number, NCT03412747.).

References

11

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 838 citations · Full text

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley et al. · Journal of the American Academy of Dermatology · 2017 · 712 citations · Full text

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich, Richard B. Warren, Mark Lebwohl et al. · New England Journal of Medicine · 2021 · 368 citations

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2021 · 276 citations

, , +6

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B. Gordon, Peter Foley, James G. Krueger et al. · The Lancet · 2021 · 258 citations

, , +6